IHM
ASND icon

Iguana Healthcare Management’s Ascendis Pharma A/S ASND Stock Holding History

Iguana Healthcare Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-30,000
Closed -$1.09M – 63
2017
Q3 		$1.09M Buy
+30,000
New +$861K 0.59% 52

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Iguana Healthcare Management's ASND Position: Q4 2017 in Review

Iguana Healthcare Management sold out of Ascendis Pharma A/S (ASND) in Q4 2017, closing a stake of 30,000 shares — an estimated $1.09M sold.

Iguana Healthcare Management first reported a position in ASND in Q3 2017 and held it in 1 quarter. The position peaked at $1.09M in Q3 2017. 65 funds tracked by Wall St. Rank hold ASND as of Q4 2017.

  • Iguana Healthcare Management reported no remaining Ascendis Pharma A/S position as of Q4 2017 after selling out during the quarter.
  • Iguana Healthcare Management sold 30,000 Ascendis Pharma A/S shares in Q4 2017, an estimated $1.09M.
  • Iguana Healthcare Management first reported a position in Ascendis Pharma A/S in Q3 2017 and held it in 1 quarter.
  • Iguana Healthcare Management's Ascendis Pharma A/S position peaked at $1.09M in Q3 2017.
  • 65 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2017.

Based on Iguana Healthcare Management's 13F filing for Q4 2017, filed 14 Feb 2018.